127 related articles for article (PubMed ID: 8440072)
1. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug.
Hirohata S; Lipsky PE
Clin Immunol Immunopathol; 1993 Jan; 66(1):43-51. PubMed ID: 8440072
[TBL] [Abstract][Full Text] [Related]
2. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells.
Hirohata S; Lipsky PE
Arthritis Rheum; 1994 Jun; 37(6):942-50. PubMed ID: 8003068
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo inhibition of activation induced T cell apoptosis by bucillamine.
Okazaki H; Sato H; Kamimura T; Hirata D; Iwamoto M; Yoshio T; Mimori A; Masuyama JI; Kano S; Minota S
J Rheumatol; 2000 Jun; 27(6):1358-64. PubMed ID: 10852254
[TBL] [Abstract][Full Text] [Related]
4. Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug.
Hirohata S; Shinohara S; Inoue T; Miyamoto T; Lipsky PE
Arthritis Rheum; 1992 Feb; 35(2):168-75. PubMed ID: 1734906
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites.
Hashimoto K; Lipsky PE
J Rheumatol; 1993 Jun; 20(6):953-7. PubMed ID: 8350330
[TBL] [Abstract][Full Text] [Related]
6. Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit.
Hirohata S
Clin Exp Rheumatol; 1992; 10(4):357-63. PubMed ID: 1356678
[TBL] [Abstract][Full Text] [Related]
7. Bucillamine suppresses human Th1 cell development by a hydrogen peroxide-independent mechanism.
Morinobu A; Wang Z; Kumagai S
J Rheumatol; 2000 Apr; 27(4):851-8. PubMed ID: 10782806
[TBL] [Abstract][Full Text] [Related]
8. Differences in the effects of the antirheumatic drugs, bucillamine and D-penicillamine, on mitogen-induced proliferation of mouse spleen cells.
Mita S; Matsunaga K
Agents Actions; 1990 Jun; 30(3-4):363-8. PubMed ID: 2386109
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of human B cell activation by gold sodium thiomalate and auranofin.
Hirohata S; Nakanishi K; Yanagida T; Kawai M; Kikuchi H; Isshi K
Clin Immunol; 1999 May; 91(2):226-33. PubMed ID: 10227815
[TBL] [Abstract][Full Text] [Related]
10. Differential influences of bucillamine and methotrexate on the generation of fibroblast-like cells from bone marrow CD34+ cells of rheumatoid arthritis patients.
Hirohata S; Yanagida T; Tomita T; Yoshikawa H
Int Immunopharmacol; 2009 Jan; 9(1):86-90. PubMed ID: 19000788
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil.
Hirohata S; Yanagida T; Kawai M; Kikuchi H
Immunopharmacology; 1999 Nov; 44(3):245-54. PubMed ID: 10598881
[TBL] [Abstract][Full Text] [Related]
12. Differential influences of gold sodium thiomalate and bucillamine on the generation of CD14+ monocyte-lineage cells from bone marrow of rheumatoid arthritis patients.
Hirohata S; Yanagida T; Hashimoto H; Tomita T; Ochi T; Nakamura H; Yoshino S
Clin Immunol Immunopathol; 1997 Sep; 84(3):290-5. PubMed ID: 9281388
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mitogen-induced response of human peripheral blood mononuclear cells by bucillamine, a new antirheumatic sulfhydryl drug.
Akamatsu T; Matsubara T; Saegusa Y; Mizuno K
Rheumatol Int; 1994; 13(5):197-201. PubMed ID: 8202663
[TBL] [Abstract][Full Text] [Related]
14. Novel in vitro effects of bucillamine: inhibitory effects on proinflammatory cytokine production and transendothelial migration of T cells.
Munakata Y; Iwata S; Dobers J; Ishii T; Nori M; Tanaka H; Morimoto C
Arthritis Rheum; 2000 Jul; 43(7):1616-23. PubMed ID: 10902767
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs--the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug.
Matsuno H; Sugiyama E; Muraguchi A; Nezuka T; Kubo T; Matsuura K; Tsuji H
Int J Immunopharmacol; 1998 Jun; 20(6):295-304. PubMed ID: 9754677
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human B cell activation by gold compounds.
Hirohata S
Clin Immunol Immunopathol; 1996 Nov; 81(2):175-81. PubMed ID: 8906749
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells.
Kikuchi H; Isshi K; Hirohata S
Int Immunopharmacol; 2004 Jan; 4(1):119-26. PubMed ID: 14975366
[TBL] [Abstract][Full Text] [Related]
18. Generation of reactive oxygen species is required for bucillamine, a novel anti-rheumatic drug, to induce apoptosis in concert with copper.
Sawada T; Hashimoto S; Furukawa H; Tohma S; Inoue T; Ito K
Immunopharmacology; 1997 Jan; 35(3):195-202. PubMed ID: 9043932
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model.
Setoguchi C; Tsuji F; Katsuta O; Okamoto M; Aono H
Mod Rheumatol; 2010 Aug; 20(4):381-8. PubMed ID: 20379758
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of expression of cyclin A in human B cells by an immunosuppressant mizoribine.
Hirohata S; Yanagida T
J Immunol; 1995 Dec; 155(11):5175-83. PubMed ID: 7594527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
